IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Metastatic Melanoma Clinical Trial

Official title:

A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04109456
• Other study ID #: IN10018-004-01
• Status: Recruiting
• Phase: Phase 1
• Start date: March 16, 2020
• Est. completion date: September 30, 2024

Study information

• Verified date: January 2024
• Source: InxMed (Shanghai) Co., Ltd.
• Contact: Eddie Xing, Dr.
• Phone: 9495200786
• Email: eddie.xing[@]inxmed.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in subjects with metastatic uveal melanoma and NRAS-mutant metastatic melanoma.

Description:

Subjects with metastatic uveal melanoma (UM) or with NRAS-mutant metastatic melanoma will be enrolled.

IN10018 will be assessed firstly as monotherapy（Part 1）, then in combination with cobimetinib (Part 2) and in combination with cobimetinib and Atezolizumab (Part 3).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: September 30, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

1. Ability to understand and willingness to sign informed consent(s).

2. Male or female subjects = 18 years at the time of signing informed consent.

3. Histologically or cytologically confirmed metastatic melanoma with subtypes limited to:

1. Metastatic uveal melanoma, or

2. Metastatic NRAS-mutant melanoma harboring an NRAS activating mutations of Q61, G12, or G13 mutation per local laboratory (including local reference laboratory) results.

4. Requirements for previous therapy:

1. Uveal melanoma: Either be treatment naïve or have failed the most recent therapy for metastatic disease, or

2. NRAS-mutant melanoma: Either be ineligible for standard of care due to the presence of various comorbidities or have failed the most recent therapy such as immunotherapy for metastatic disease.

3. Have failed immunotherapy therapy (anti-PD-1 or anti-PD-L1) alone or in combination with other agents for metastatic disease either with no initial response or disease progression after an initial response. (Part 3)

4. Received a minimum of two cycles of anti-PD-1/PD-L1 therapy. (Part 3)

5. Consent to undergo tumor biopsies of accessible lesions, before and during treatment and at radiographic progression, for biomarker analyses (site dependent).

6. At least one measurable lesion can be accurately measured per RECIST 1.1 by investigator.

7. ECOG performance status of 0 or 1.

8. Life expectancy of at least 3 months as assessed by investigator.

9. Availability of fresh tumor tissue and/or archival tumor tissue at Screening if agreed by subjects.

10. Must have recovered from all AEs due to previous therapies to = Grade 1 (CTCAE 5.0) or stable status as assessed by investigator.

11. Adequate bone marrow, liver, renal, and coagulation function within 5 days prior to first dose of study treatment.

12. A male subject must agree to use contraception as detailed in Appendix 4 of this protocol during the treatment period and through 30 days after the last dose of study treatment and must refrain from donating sperm during this period.

13. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 4. OR

2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 4 during the treatment period and through 30 days after the last dose of study treatment.

Key Exclusion Criteria:

1. Has had major surgery or significant traumatic injury within 28 days prior to first dose of study treatment, or anticipation of the need for major surgery during study treatment.

2. Has received prior systemic, intrahepatic, or sphere anticancer therapy including investigational agents within 14 days or less than 5 half-lives (whichever is shorter) of chemotherapy or targeted therapy, or within 28 days of immunotherapy, prior to first dose of study treatment.

3. Has received prior radiotherapy or radioactive chemotherapy within 14 days prior to first dose of study treatment.

4. Has received prior treatment of any FAK inhibitor (Parts 1, 2 and 3), or prior treatment of any MEK inhibitor (Parts 2 and 3 only).

5. Has a known previous or concurrent cancer that is distinct in primary site or histology from current melanoma within 3 years prior to first dose of study treatment, except for curatively treated cancers such as cervical carcinoma in situ and indolent cancers with very low likelihood of relapse or progress per investigator judgement.

6. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

7. Diabetes mellitus, insulin dependent and non-insulin dependent with HBA1C > 6.5%, microalbuminuria > 150 mg (24-h collection), and CrCL of < 45ml/min with an adequate 24-hour urine collection.

8. Prior history of Alport syndrome.

9. Recent medical history (with the last 1-year) of acute renal injury, Goodpasture's Syndrome, IgA nephropathy, focal segmental glomerulosclerosis, nephrotic syndrome, parenteral drug abuse, recurrent pyelonephritis, systemic lupus erythematosus, uncontrolled hypertension, vasculitis, and chronic illnesses with potential underlying glomerular renal disease.

10. Has contraindications to anti-PD-1 or anti-PD-L1 immunotherapy (Part 3).

11. Has received prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA4 immunotherapy and was discontinued for significant immunotherapy-related adverse events (Part 3).

12. Current treatment with anti-viral therapy for HBV (Part 3).

13. Prior allogeneic stem cell or solid organ transplantation.

14. Active tuberculosis

15. Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina (Part 3).

16. Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions: Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study. (Part 3).

17. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on previous chest computed tomography (CT) scan.

18. Has a history of major cardiovascular, cerebrovascular, or thromboembolic diseases (e.g., congestive heart failure, acute myocardial infarction, unstable angina, atrial fibrillation, ventricular tachyarrhythmia, uncontrolled hypertension, stroke, transient ischemic attack, deep vein thrombosis or pulmonary embolism) within 6 months before first dose of study treatment, or has any of the following abnormality:

• QTc interval > 480 msec (Fridericia formula), (patients with right bundle branch block is not required to have QTc if the block is stable and assessed as not clinically significant by the PI),

• Left ventricular ejection fraction (LVEF) < 50%,

• Arrhythmia with clinical significance, or

• Other heart diseases with clinical significance.

19. History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/ central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), neovascular macular degeneration, or uncontrolled glaucoma with intra-ocular pressures >21 mmHg in the eye(s) unaffected by melanoma. (Parts 2 and 3)

20. Has known uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage prior to the first dose of study treatment.

21. Has malabsorption syndrome or inability to take oral drugs.

22. Has clinically significant gastrointestinal abnormalities including uncontrolled gastrointestinal inflammatory lesions (Crohn's disease, or ulcerative colitis in active or uncontrolled gastrointestinal bleeding).

23. Known allergy or hypersensitivity to IN10018 cobimetinib and/or atezolizumab, or their ingredients.

24. Has had an active infection requiring systemic therapy within 14 days prior to the first dose of study treatment.

25. Has known human immunodeficiency virus (HIV) infection.

26. Has known active Hepatitis B or Hepatitis C virus infection.

27. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

28. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the study.

29. Has had used below CYP3A inhibitors/inducers and P-gp inhibitors within 14 days prior to first dose of study treatment, or anticipation of the need to use them during study treatment:

• Part 1: Strong CYP3A inhibitors/inducers and P-gp inhibitors are prohibited at least 14 days prior to initiation of and during study treatment.

• Parts 2 and 3: Moderate and Strong CYP3A inhibitors/inducers and P-gp inhibitors are prohibited at least 14 days prior to initiation of and during study treatment.

Related Conditions & MeSH terms

• Melanoma
• Metastatic Melanoma

Intervention

Drug:
• IN10018
100 mg or 50mg, orally once daily continuously;
• Cobimetinib
60mg , orally once daily from day 1 to day 21 in a 28-day cycle

Biological:
• Atezolizumab
biweekly 840 mg dose will be used in this study starting from Cycle 2.

Locations

Country	Name	City	State
Australia	The Alfred Hospital	Melbourne	Victoria
Australia	Linear Clinical Research	Nedlands	Western Australia
Australia	St Vincent Hospital Sydney	Sydney	New South Wales
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	MD Anderson	Houston	Texas
United States	Sylvester Comprehensive Cancer Center.	Miami	Florida
United States	Columbia University Medical Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
InxMed (Shanghai) Co., Ltd.

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To explore potential predictive biomarkers	in all 3 parts	through study completion, an average of 5 year
Primary	Safety and tolerability of IN10018 monotherapy	Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment	The first 21-day cycle
Primary	Safety and tolerability of IN10018 in combination with cobimetinib	Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment	The first 28-day cycle
Primary	Safety and tolerability of IN10018 in combination with cobimetinib and atezolizumab	Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment	All treatment period
Secondary	Pharmacokinetics (PK) : Cmax	Peak Plasma Concentration (Cmax)	Cycle 1 and Cycle 3
Secondary	Pharmacokinetics (PK) : AUC	Area under the plasma concentration versus time curve (AUC)	Cycle 1 and Cycle 3
Secondary	Pharmacokinetics (PK) : tmax	Time to Cmax (tmax)	Cycle 1 and Cycle 3
Secondary	Pharmacokinetics (PK) : t1/2	Elimination half-life (t1/2)	Cycle 1 and Cycle 3
Secondary	Pharmacokinetics (PK) : CL/F	apparent clearance (CL/F)	Cycle 1 and Cycle 3
Secondary	Pharmacokinetics (PK) : Vd	Apparent volume of distribution(Vd)	Cycle 1 and Cycle 3
Secondary	Overall Response Rates using RECiST1.1 criteria	Proportion of participants with (complete response, partial response, stable disease, progressive disease) in all 3 parts	1 year
Secondary	Disease Control Rate using RECiST1.1 criteria	Proportion of subjects who have disease control (CR, PR or stable disease (SD)) in all 3 parts	1 year
Secondary	duration of response (DOR)	For subjects who demonstrate CR or PR, DOR is defined as the time from first evidence of CR or PR until PD or death due to any cause, whichever occurs first in all 3 parts	1 year
Secondary	progression free survival (PFS)	PFS is defined as the time from the first day of study treatment to the first disease progression or death due to any cause, whichever occurs first in all 3 parts	1 year
Secondary	overall survival (OS)	OS is defined as the time from the first day of study treatment to death due to any cause in all 3 parts	1 year